5 observations on Smith & Nephew’s stock rating downgrade

Zacks downgraded Smith & Nephew from a “hold” rating to a “sell” rating, according to a Dakota Financial News report.

Advertisement

Here are five observations:

 

1. The company currently has a consensus target price of $40.97.

 

2. Smith & Nephew has a one-year low of $28.87 and a one-year high of $39.80.

 

3. The stock’s 50-day moving average is $34.50 and its 200-day moving average is $35.04.

 

4. The company has a market cap of $15.94 billion.

 

5. In June, Smith & Nephew announced plans to acquire Zimmer’s unicondylar knee system in the United States market.

 

More articles on devices:
NuVasive names new executive vice president — 5 key notes
J&J Orthopedics sales drop 5.6% in Q2: 5 key notes
Surgical Science features Zyga’s SImmetry SI joint fusion system: 5 key notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.